SCHEMBL1574840

SCHEMBL1574840

COc1cc(CN2CCN(C3CN(C(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)C3)CC2)cc(OC)c1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TSHR P16473 2/20 0.45
CYP2C9 P11712 2/20 0.45
KDM4E B2RXH2 1/20 0.45
ALOX15 P16050 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
FAAH O00519 3/20 0.45
POLB P06746 2/20 0.45
CYP2D6 P10635 1/20 0.44
PRKAB2 O43741 2/20 0.44
PRKAG1 P54619 2/20 0.44
PRKAA2 P54646 2/20 0.44
PRKAA1 Q13131 2/20 0.44
PRKAG3 Q9UGI9 2/20 0.44
PRKAG2 Q9UGJ0 2/20 0.44
PRKAB1 Q9Y478 2/20 0.44
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1576044 0.90 FAAH (0.58) MEN1KMT2AKDM4EFAAHPRKAB2
SCHEMBL1575675 0.86 FAAH (0.49) MEN1KMT2AFAAHPRKAB2PRKAG1
SCHEMBL1575484 0.86 FAAH (0.49) FAAHPRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL1575324 0.86 PRKAB2 (0.60) MEN1KMT2ACYP2C9FAAHPRKAB2
SCHEMBL1576196 0.86 TSHR (0.52) MEN1KMT2ATSHRKDM4EALOX15
SCHEMBL1575036 0.85 PRKAB2 (0.44) MEN1KMT2ACYP2C9KDM4EHSD17B10
SCHEMBL1576012 0.85 POLB (0.45) TSHRALOX15HSD17B10FAAHPOLB
SCHEMBL1575670 0.84 TSHR (0.54) MEN1KMT2ATSHRKDM4EALOX15
SCHEMBL1575395 0.84 FAAH (0.60) MEN1KMT2AFAAHPOLBPRKAB2
SCHEMBL1575591 0.83 FAAH (0.61) FAAHPRKAB2PRKAG1PRKAA2PRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB MEN1 1113/4885KMT2A 2539/4885TSHR 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.